This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
No
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
The most common travel illness, affecting 20–60% of travelers to developing countries. Usually self-limiting. Carry oral rehydration salts and know when to seek medical care (bloody stool, high fever, signs of dehydration).
The most common travel-related illness, affecting 20-60% of travelers to developing regions. Usually self-limiting within 3-5 days. Caused primarily by bacterial pathogens from contaminated food and water.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Diarrhea | 100% | Moderate | Early |
| Abdominal cramps | 80% | Moderate | Early |
| Nausea | 50% | Mild | Early |
| Vomiting | 25% | Mild | Early |
| Dehydration | 40% | Moderate | Peak |
| Bloody diarrhea | 15% | Severe | Peak |
| Bloody stool | 12% | Severe | Peak |
| Chills | 10% | Mild | Peak |
| Myalgia | 20% | Mild | Peak |
| Fatigue | 50% | Mild | Late |
| Constipation | 5% | Mild | Late |
| Abdominal pain | 60% | Mild | Any phase |
| Bloating | 45% | Mild | Any phase |
| Loss of appetite | 65% | Mild | Any phase |
| Malaise | 55% | Mild | Any phase |
| Fever | 20% | Mild | Any phase |
| Headache | 30% | Mild | Any phase |
Travelers' diarrhea (TD) is the most common health problem affecting international travelers, characterized by the passage of three or more unformed stools within a 24-hour period accompanied by at least one additional symptom such as abdominal cramps, nausea, vomiting, fever, fecal urgency, or tenesmus. It affects an estimated 30–70% of travelers to high-risk destinations, depending on the origin and destination of travel, season, and individual risk factors.
TD is a syndrome rather than a single disease, caused by a wide variety of enteric pathogens acquired through ingestion of contaminated food or water. Enterotoxigenic Escherichia coli (ETEC) is the most commonly identified bacterial cause worldwide, but the spectrum of causative agents varies by geographic region. In Southeast Asia, Campylobacter species predominate, while norovirus and other viral pathogens account for a growing proportion of identified cases globally.
Despite being usually self-limiting, travelers' diarrhea has significant impact: it disrupts travel itineraries in up to 40% of affected travelers, confines 20% to bed, and leads to changes in travel plans in approximately 1%. Less than 1% require hospitalization. The economic impact includes lost travel days, medical costs, and reduced productivity during and after travel.
The etiology of travelers' diarrhea is diverse. Bacterial pathogens account for approximately 60–80% of identified cases: ETEC (20–30%), Campylobacter (5–30%, highest in Southeast Asia), Salmonella (5–10%), Shigella (5–10%), and Aeromonas, Plesiomonas, and Vibrio species in smaller proportions. Viral pathogens, particularly norovirus, cause 10–20% of cases. Parasitic causes — primarily Giardia lamblia, Cryptosporidium, Cyclospora cayetanensis, and Entamoeba histolytica — account for less than 10% of acute cases but are disproportionately represented in persistent diarrhea (lasting >14 days).
Transmission occurs almost exclusively through the fecal-oral route via contaminated food, water, or direct person-to-person contact. High-risk foods include raw or undercooked meats, unpasteurized dairy, raw fruits and vegetables (especially leafy greens), street food, and ice made from untreated water. Risk is highest in South and Southeast Asia, Sub-Saharan Africa, and Central and South America, and lower in Southern Europe and the Caribbean.
The incubation period varies with the causative pathogen: bacterial TD typically manifests within 6–72 hours, viral TD within 12–48 hours, and parasitic TD within 1–3 weeks. Most episodes begin within the first week of travel. The illness is generally self-limiting, with 90% of cases resolving within 3–5 days without specific treatment.
While travelers' diarrhea is usually benign, certain features require urgent medical evaluation. Seek immediate care for signs of severe dehydration: markedly decreased urine output (dark concentrated urine or no urine for 8+ hours), rapid heart rate, dizziness upon standing, dry mouth and tongue, sunken eyes, or confusion. Dehydration progresses more rapidly in hot climates and at altitude.
Bloody diarrhea (dysentery) always warrants prompt medical attention. Blood in the stool indicates mucosal invasion by pathogens such as Shigella, Campylobacter, or Entamoeba histolytica and requires appropriate antibiotic or antiparasitic treatment. High fever (>39°C/102°F) accompanying diarrhea suggests an invasive infection and merits evaluation, particularly to exclude malaria in travelers returning from endemic areas, as malaria can present with gastrointestinal symptoms.
Other red flags include: diarrhea lasting more than 72 hours despite self-treatment, inability to tolerate oral fluids due to persistent vomiting, severe abdominal pain (particularly if localized rather than diffuse, which may suggest surgical pathology), and symptoms in travelers with underlying conditions that increase the risk of complications — immunosuppression, inflammatory bowel disease, chronic kidney or liver disease, and pregnancy. In young children and the elderly, the threshold for seeking care should be lower.
Most common signs and symptoms
The clinical presentation of travelers' diarrhea ranges from mild inconvenience to incapacitating illness. The classic presentation begins with sudden onset of loose, watery stools (3 or more per day), accompanied by abdominal cramps that are often colicky and periumbilical. Nausea, bloating, and fecal urgency are common. Fever is present in a minority of cases (10–30%) and typically indicates an invasive pathogen.
Travelers' diarrhea is classified by severity: mild (1–2 loose stools per day without distressing symptoms, tolerable and not interfering with activities), moderate (3 or more stools per day, or fewer with distressing symptoms such as cramps, nausea, or fever, partially disabling), and severe (incapacitating diarrhea, or any dysentery — passage of grossly bloody stools). This classification guides treatment decisions.
Dysentery — the passage of bloody or mucoid stools, often with fever, tenesmus, and small-volume frequent stools — indicates an invasive pathogen, most commonly Shigella, enteroinvasive E. coli (EIEC), or Campylobacter, and always warrants antibiotic treatment. Some patients experience post-infectious symptoms: fatigue, intermittent abdominal discomfort, and altered bowel habits may persist for weeks after the acute episode resolves, and 3–17% develop post-infectious irritable bowel syndrome (PI-IBS).
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Common causative agents:
Bacterial (80–85%): ETEC (most common), Campylobacter, Salmonella, Shigella.
Viral (5–15%): Norovirus.
Parasitic (5–10%): Giardia, Cryptosporidium, Entamoeba (longer incubation, prolonged symptoms).
Treatment principles: Oral rehydration first. Loperamide for symptom relief (non-bloody diarrhea only). Azithromycin (empiric antibiotic if needed).
How this disease is identified
In the majority of travelers' diarrhea episodes, diagnosis is clinical and empiric — treatment is initiated based on the clinical presentation without microbiological confirmation, as the illness is usually self-limiting and results would not return before symptoms resolve. The clinical diagnosis requires three or more unformed stools within 24 hours plus at least one accompanying symptom.
Microbiological testing is indicated in specific circumstances: persistent diarrhea lasting more than 14 days (to identify parasitic causes), dysentery (bloody stools), severe or worsening illness despite empiric antibiotic treatment, and diarrhea in immunocompromised patients. Multiplex PCR stool panels (e.g., BioFire FilmArray GI Panel) can simultaneously detect over 20 bacterial, viral, and parasitic pathogens from a single specimen and have largely replaced traditional stool culture and microscopy in well-resourced settings.
When laboratory testing is performed, stool culture remains the reference standard for bacterial pathogens and allows antimicrobial susceptibility testing — particularly valuable given rising antibiotic resistance. Stool microscopy for ova and parasites (O&P) should be performed on at least three specimens collected on separate days if parasitic infection is suspected. Giardia and Cryptosporidium antigen tests offer higher sensitivity than microscopy. C. difficile testing should be considered in patients with recent antibiotic use or healthcare exposure.
Available treatment methods
Treatment of travelers' diarrhea is guided by severity. For mild cases (1–2 loose stools/day, tolerable symptoms), the primary intervention is maintaining hydration with oral rehydration solutions (ORS), clear broths, or electrolyte-containing beverages. Loperamide (Imodium) may be used for symptomatic relief when access to toilets is limited. Bismuth subsalicylate (Pepto-Bismol) provides modest symptom reduction but requires frequent dosing.
For moderate cases (3+ stools/day with distressing symptoms), antimotility agents combined with antibiotics provide the fastest resolution. Azithromycin (single 1,000 mg dose or 500 mg daily for 3 days) is the preferred first-line antibiotic globally due to increasing fluoroquinolone resistance. Rifaximin (200 mg three times daily for 3 days) is an effective alternative for non-invasive, non-bloody watery diarrhea and has the advantage of minimal systemic absorption. Fluoroquinolones (ciprofloxacin 500 mg twice daily for 1–3 days) remain effective in many regions but resistance is high in Southeast Asia and parts of South Asia.
For severe cases and dysentery, azithromycin is the treatment of choice. Loperamide should be used with caution (and avoided entirely in patients with high fever or bloody stools, as it may prolong invasive infections). Intravenous fluids may be required for patients unable to maintain oral hydration. Persistent diarrhea (>14 days) should prompt stool testing for parasites (Giardia, Cryptosporidium, Cyclospora) and targeted treatment with metronidazole, nitazoxanide, or trimethoprim-sulfamethoxazole as appropriate.
Most cases are effectively treated with early diagnosis.
How to protect yourself
The traditional mantra for preventing travelers' diarrhea — "boil it, cook it, peel it, or forget it" — remains the foundation of dietary advice, though studies suggest that adherence is difficult to maintain and provides only partial protection. Key food and water precautions include: drinking only bottled, boiled, or chemically treated water; avoiding ice in beverages (unless confirmed made from purified water); eating only thoroughly cooked, piping-hot foods; peeling fruits and vegetables yourself; and avoiding street vendors, buffets with prolonged food exposure, and raw salads.
Hand hygiene is an underappreciated but critical prevention measure. Frequent handwashing with soap and water before eating and after using the toilet, or use of alcohol-based hand sanitizer (≥60% alcohol) when water is unavailable, reduces transmission of all enteric pathogens. Travelers should carry a small bottle of hand sanitizer as a routine travel item.
Chemoprophylaxis with bismuth subsalicylate (Pepto-Bismol, 2 tablets four times daily) provides approximately 65% protection but is impractical for trips exceeding 3 weeks due to the pill burden and potential side effects (black tongue and stool, tinnitus). Routine antibiotic prophylaxis is not recommended due to the risk of promoting antimicrobial resistance, adverse effects, and the availability of effective self-treatment. Rifaximin prophylaxis may be considered for short trips to high-risk areas in travelers for whom even brief illness would be unacceptable (competitive athletes, essential business travelers).
Preparation is the best protection.
Travelers' diarrhea risk is broadly categorized by destination: high-risk (30–70% attack rate) includes South and Southeast Asia, Sub-Saharan Africa, Central and South America, and the Middle East; intermediate-risk (10–20%) includes Southern Europe, the Caribbean, and South Africa; low-risk (<10%) includes North America, Western Europe, Japan, Australia, and New Zealand.
Every traveler to a high-risk destination should carry a self-treatment kit containing: oral rehydration salt packets (ORS), loperamide (for symptomatic relief), and a course of antibiotics (typically azithromycin 500 mg × 3 days, or a single 1,000 mg dose for rapid treatment). Discuss this with a travel medicine provider before departure to obtain a prescription and clear guidance on when and how to self-treat.
Know when self-treatment is appropriate and when to seek professional care. Self-treat with antibiotics for moderate to severe watery diarrhea that does not improve within 24 hours. Seek medical attention for bloody stools, fever above 39°C, symptoms lasting beyond 72 hours despite self-treatment, severe dehydration, or any concern about malaria. After returning home, consult a physician if diarrhea persists beyond 14 days, as this warrants investigation for parasitic infection or other causes of persistent diarrhea.
Statistics and geographic data
Travelers' diarrhea is by far the most frequent health problem of international travelers, with an estimated 10–20 million cases annually among the 1.4 billion international tourist arrivals worldwide. The overall incidence has declined somewhat over recent decades due to improvements in food safety and water sanitation in many developing countries, but it remains a persistent and significant issue.
The microbial etiology has shifted over time. While ETEC remains the single most commonly identified bacterial pathogen globally (15–30% of cases), the proportion attributable to viral pathogens — particularly norovirus — has increased as diagnostic sensitivity has improved with multiplex PCR panels. In approximately 20–40% of TD episodes, no pathogen is identified even with comprehensive testing, suggesting either novel or difficult-to-detect pathogens, or non-infectious dietary causes.
Geographic variation in pathogen distribution has important clinical implications. Campylobacter dominates in Southeast Asia (particularly Thailand) and shows high fluoroquinolone resistance, making azithromycin the preferred treatment in that region. Shigella is increasingly drug-resistant globally, with extensively drug-resistant (XDR) strains emerging in South Asia. ETEC-focused vaccine candidates are in clinical trials but none have yet achieved licensure. The rise of antimicrobial resistance among TD pathogens is a growing concern that reinforces the recommendation against prophylactic antibiotic use.
Who is most at risk
The dominant risk factor for travelers' diarrhea is the destination. Travel from a high-income to a low- or middle-income country creates a gradient of exposure to novel enteric pathogens against which the traveler has no pre-existing immunity. Within destinations, specific high-risk behaviors include eating street food, consuming raw vegetables and salads, drinking tap water or beverages with ice, and eating at buffets where food has been at ambient temperature for prolonged periods.
Host factors significantly influence susceptibility. Young adults (18–30 years) have the highest attack rates, likely due to more adventurous dietary habits rather than immunological factors. Travelers with reduced gastric acidity — whether from proton pump inhibitors (PPIs), H2 blockers, or previous gastric surgery — are at substantially increased risk, as gastric acid is a primary defense against ingested pathogens. Immunocompromised travelers, including those with HIV, organ transplant recipients, and patients on immunosuppressive therapy, face higher risk of both acquisition and complicated disease.
Travel style matters considerably. Backpackers, adventure travelers, and those visiting friends and relatives (VFR travelers) have higher rates than package tour or business travelers. Duration of stay correlates with cumulative risk, though the daily rate decreases after the first 2 weeks as some adaptive immunity develops. The rainy or monsoon season in tropical destinations is associated with higher pathogen contamination of food and water sources. Previous episodes of travelers' diarrhea do not reliably protect against future episodes, as the causative pathogens are diverse.
Potential complications
The most immediate complication of travelers' diarrhea is dehydration, which can develop rapidly in hot climates, at altitude, or with severe vomiting that prevents oral fluid intake. While rarely life-threatening in otherwise healthy adults with access to rehydration fluids, dehydration poses particular risk to young children, the elderly, and those with underlying cardiovascular or renal disease. Severe dehydration can lead to acute kidney injury, cardiac arrhythmias, and hemodynamic collapse.
The most clinically significant long-term complication is post-infectious irritable bowel syndrome (PI-IBS), which develops in an estimated 3–17% of travelers' diarrhea patients. PI-IBS is characterized by persistent abdominal pain, bloating, and altered bowel habits (diarrhea-predominant or mixed pattern) that can last for months to years after the acute infection has resolved. Risk factors for PI-IBS include more severe initial illness, female sex, and pre-existing anxiety or depression. The pathogenesis involves persistent low-grade gut inflammation, altered intestinal permeability, and changes in the gut microbiome.
Other complications include reactive arthritis (particularly following Salmonella, Shigella, Campylobacter, or Yersinia infection), Guillain-Barré syndrome (rare, associated with Campylobacter), and hemolytic uremic syndrome (rare, associated with Shiga toxin-producing E. coli). Persistent parasitic infections, particularly giardiasis, can cause malabsorption, weight loss, and lactose intolerance lasting weeks to months if not appropriately treated. Antibiotic treatment of TD, while effective for the acute episode, may itself cause complications including Clostridioides difficile infection and disruption of the gut microbiome.
Expected outcomes and recovery
Excellent prognosis. Self-limiting in >90% of cases within 3–5 days.
Most cases are mild to moderate and resolve without specific treatment.
Dehydration is the main risk (especially in children, elderly, and those with chronic illness).
Antibiotic treatment shortens duration from 3–5 days to 1–2 days.
Post-infectious IBS: 3–17% of travelers' diarrhea cases develop post-infectious irritable bowel syndrome (PI-IBS), lasting months to years.
Rare severe complications: Hemolytic uremic syndrome (HUS) with STEC, reactive arthritis (Salmonella, Shigella, Campylobacter), Guillain-Barré syndrome (Campylobacter).
Etiology affects duration: Viral: 1–3 days. Bacterial: 3–5 days. Parasitic (Giardia, Cryptosporidium): weeks if untreated.
The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.